Zoetis (NYSE:ZTS) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on March 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Zoetis Trading Up 2.4%

NYSE:ZTS opened at $119.66 on Thursday. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock has a market capitalization of $50.51 billion, a PE ratio of 19.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The business’s 50-day simple moving average is $122.39 and its 200-day simple moving average is $127.49.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ZTS. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $152.91.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC boosted its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. Global Wealth Strategies & Associates bought a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $30,000. Finally, KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the 3rd quarter worth approximately $31,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.